» Articles » PMID: 37353617

Chromatin-associated OGT Promotes the Malignant Progression of Hepatocellular Carcinoma by Activating ZNF263

Overview
Journal Oncogene
Date 2023 Jun 23
PMID 37353617
Authors
Affiliations
Soon will be listed here.
Abstract

Reversible and dynamic O-GlcNAcylation regulates vast networks of highly coordinated cellular and nuclear processes. Although dysregulation of the sole enzyme O-GlcNAc transferase (OGT) was shown to be associated with the progression of hepatocellular carcinoma (HCC), the mechanisms by which OGT controls the cis-regulatory elements in the genome and performs transcriptional functions remain unclear. Here, we demonstrate that elevated OGT levels enhance HCC proliferation and metastasis, in vitro and in vivo, by orchestrating the transcription of numerous regulators of malignancy. Diverse transcriptional regulators are recruited by OGT in HCC cells undergoing malignant progression, which shapes genome-wide OGT chromatin cis-element occupation. Furthermore, an unrecognized cooperation between ZNF263 and OGT is crucial for activating downstream transcription in HCC cells. We reveal that O-GlcNAcylation of Ser662 is responsible for the chromatin association of ZNF263 at candidate gene promoters and the OGT-facilitated HCC malignant phenotypes. Our data establish the importance of aberrant OGT activity and ZNF263 O-GlcNAcylation in the malignant progression of HCC and support the investigation of OGT as a therapeutic target for HCC.

Citing Articles

Zinc finger protein 263 promotes colorectal cancer cell progression by activating STAT3 and enhancing chemoradiotherapy resistance.

Du Y, Chen Y, Yan Z, Yang J, Da M Sci Rep. 2024; 14(1):21827.

PMID: 39294234 PMC: 11410824. DOI: 10.1038/s41598-024-72636-0.


The roles of OGT and its mechanisms in cancer.

Liu X, Wang J, Xiang Y, Wang K, Yan D, Tong Y Cell Biosci. 2024; 14(1):121.

PMID: 39285476 PMC: 11406787. DOI: 10.1186/s13578-024-01301-w.


Resveratrol suppresses liver cancer progression by downregulating AKR1C3: targeting HCC with HSA nanomaterial as a carrier to enhance therapeutic efficacy.

Wang Y, Su L, Hu Z, Peng S, Li N, Fu H Apoptosis. 2024; 29(9-10):1429-1453.

PMID: 39023830 DOI: 10.1007/s10495-024-01995-w.

References
1.
Llovet J, Castet F, Heikenwalder M, Maini M, Mazzaferro V, Pinato D . Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021; 19(3):151-172. DOI: 10.1038/s41571-021-00573-2. View

2.
Craig A, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A . Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019; 17(3):139-152. DOI: 10.1038/s41575-019-0229-4. View

3.
Giannelli G, Koudelkova P, Dituri F, Mikulits W . Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016; 65(4):798-808. DOI: 10.1016/j.jhep.2016.05.007. View

4.
Katyal S, Oliver 3rd J, Peterson M, Ferris J, Carr B, BARON R . Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000; 216(3):698-703. DOI: 10.1148/radiology.216.3.r00se24698. View

5.
Slawson C, Hart G . O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer. 2011; 11(9):678-84. PMC: 3291174. DOI: 10.1038/nrc3114. View